Skip to main content

Table 2 Results of univariate analysis of predictors for overall survival in three subgroups

From: Prognostic factors in colorectal liver metastases patients with various tumor numbers treated by liver resection: a single-center, retrospective study

Risk factors

N = 1 (n = 375)

N = 2 4 (n = 424)

N ≥ 5 (n = 296)

HR

95%CI

p

HR

95%CI

p

HR

95%CI

p

Age group

 < 60

Ref

  

Ref

  

Ref

  

 ≥ 60

0.995

0.713–1.388

0.975

0.879

0.654–1.182

0.394

0.899

0.609–1.326

0.591

Gender

 Male

Ref

  

Ref

  

Ref

  

 Female

0.781

0.558–1.095

0.152

0.787

0.583–1.062

0.118

1.005

0.680–1.484

0.981

Primary site

 Left

Ref

  

Ref

  

Ref

  

 Right

1.916

1.309–2.803

0.001

1.143

0.790–1.654

0.478

1.083

0.682–1.719

0.736

Primary tumor T stage

 T1−2

Ref

  

Ref

  

Ref

  

 T3−4

1.396

0.754–2.584

0.289

3.239

1.433–7.323

0.005

1.622

0.713–3.693

0.249

Primary tumor lymph node status

 Negative

Ref

  

Ref

  

Ref

  

 Positive

1.153

0.813–1.636

0.425

1.763

1.251–2.485

0.001

1.750

1.138–2.693

0.011

Disease-free interval

 ≥ 12 m

Ref

  

Ref

  

Ref

  

 < 12 m

1.235

0.874–1.745

0.232

1.031

0.675–1.575

0.888

0.673

0.328–1.382

0.281

Distribution of liver metastases

 Unilobar

Ref

  

Ref

  

Ref

  

 Bilobar

1.396

0.816–2.391

0.224

1.115

0.820–1.516

0.489

0.979

0.583–1.643

0.935

Maximum tumor diameter

 < 5 cm

Ref

  

Ref

  

Ref

  

 ≥ 5 cm

1.343

0.901–2.004

0.148

2.189

1.491–3.213

0.000

2.564

1.486–4.426

0.001

Pulmonary metastases

 Negative

Ref

  

Ref

  

Ref

  

 Positive

1.839

1.142–2.962

0.012

1.759

1.150–2.690

0.009

1.702

1.003-2.888

0.049

RAS mutation

Wild

Ref

  

Ref

  

Ref

  

 Mutation

1.973

1.412–2.757

0.000

1.602

1.188–2.162

0.002

2.913

2.011–4.219

0.000

Preoperative chemotherapy

 No

Ref

  

Ref

  

Ref

  

 Yes

0.916

0.656–1.279

0.607

0.893

0.618–1.290

0.547

0.948

0.462–1.947

0.885

CEA level (ng/ml)

 < 200

Ref

  

Ref

  

Ref

  

 ≥ 200

4.179

2.041–8.557

0.000

2.162

1.140–4.102

0.018

1.081

0.341–3.427

0.895

CA19-9 level (IU/ml)

 < 50

Ref

  

Ref

  

Ref

  

 ≥ 50

2.175

1.543–3.067

0.000

2.355

1.712–3.239

0.000

1.362

0.904–2.052

0.140

Margin status

 R0

Ref

  

Ref

  

Ref

  

 R1

1.201

0.664–2.171

0.544

1.237

0.820–1.864

0.310

1.070

0.720–1.590

0.737

 R2

1.935

0.479–7.824

0.354

1.025

0.254–4.138

0.973

0.746

0.183–3.034

0.682

Hepatic resection

 Minor

Ref

  

Ref

  

Ref

  

 Major

1.324

0.797–2.199

0.279

1.298

0.908–1.856

0.152

1.190

0.826–1.714

0.351

Perioperative RBC transfusion

 No

Ref

  

Ref

  

Ref

  

 Yes

1.490

0.757–2.933

0.248

1.327

0.833–2.116

0.234

1.252

0.780–2.010

0.352

Intraoperative ablation

 No

Ref

  

Ref

  

Ref

  

 Yes

0.293

0.041–2.094

0.221

0.765

0.474–1.235

0.273

0.766

0.506–1.161

0.209

Simultaneous resection

 No

Ref

  

Ref

  

Ref

  

 Yes

1.385

0.914–2.097

0.125

0.871

0.615–1.232

0.434

0.843

0.549–1.294

0.434

  1. Abbreviations: LM liver metastases, RAS rat sarcoma viral oncogene homolog, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, RBC red blood cell
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us